David M. Woods

发表

Teaching Tip: Active Learning Using Debates in an IT Strategy Course

David M. Woods, 2020, J. Inf. Syst. Educ..

An IT Strategy Course: Why and How

David M. Woods, Elizabeth V. Howard, David M. Woods, 2015 .

Introducing IT Strategy in an Introductory Course

David M. Woods, 2016 .

Using agile methods to scaffold team projects in an it ethics course

David M. Woods, Andrea R. Hulshult, 2018 .

Introducing the Cloud in an Introductory IT Course

David M. Woods, 2018 .

Histone Deacetylases as Targets for Melanoma Immunotherapy

David M. Woods, D. Woods, 2013 .

Predictors of responses to immune checkpoint blockade in advanced melanoma

David M. Woods, Y. Koguchi, G. Kroemer, 2017, Nature Communications.

Regulation of the Jak/STATs Pathways by Histone Deacetylases

David M. Woods, D. Woods, E. Seto, 2014 .

Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes.

David M. Woods, Santi S. Adavani, P. Chattopadhyay, 2020, JCI insight.

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition

David M. Woods, A. Laino, D. Woods, 2020, Journal for immunotherapy of cancer.

T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.

David M. Woods, E. Seto, J. Pinilla-Ibarz, 2017, Blood.

Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function.

David M. Woods, D. Woods, J. Pinilla-Ibarz, 2015, Molecular immunology.

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma

David M. Woods, A. Laino, D. Woods, 2018, Clinical Cancer Research.

Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma

David M. Woods, A. Laino, D. Woods, 2022, Melanoma research.

Simultaneous assessment of eight phosphorylated STAT residues in T-cells by flow cytometry

David M. Woods, P. Chattopadhyay, D. Woods, 2021, bioRxiv.

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

David M. Woods, D. Woods, J. Weber, 2015, Cancer Immunology Research.

Targeting histone deacetylase 6 mediates a dual anti‐melanoma effect: Enhanced antitumor immunity and impaired cell proliferation

David M. Woods, D. Woods, K. Smalley, 2015, Molecular oncology.

Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells

David M. Woods, A. Laino, D. Woods, 2020, Clinical Cancer Research.

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma

David M. Woods, M. Vignali, R. Wilson, 2019, Cancer Immunology Research.

A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance.

David M. Woods, J. Weber, A. Puranik, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

David M. Woods, J. Christensen, D. Woods, 2018, Cancer Immunology, Immunotherapy.

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

David M. Woods, I. Dolgalev, A. Laino, 2019, Journal of Immunotherapy for Cancer.

PhenoComb: a discovery tool to assess complex phenotypes in high-dimensional single-cell datasets

David M. Woods, C. Amato, P. Burke, 2022, bioRxiv.

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma

David M. Woods, A. Laino, D. Woods, 2020, Journal for ImmunoTherapy of Cancer.

A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs

David M. Woods, D. Woods, E. Seto, 2014, The Journal of Immunology.

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity

David M. Woods, P. Atadja, D. Woods, 2013, Melanoma research.